Breaking News

Akorn Completes VersaPharm Acquisition

August 12, 2014

Expands presence in dermatology market

Akorn, Inc. has completed its acquisition of VPI Holdings Corp., the parent company of VersaPharm Inc., for $440 million, expanding its presence in the dermatology market. The transaction is expected to add $90 to $100 million in annual revenues. 
"We are excited to announce that we have completed the acquisition of VersaPharm," said Raj Rai, chief executive officer of Akorn. "This highly strategic acquisition further strengthens our niche portfolio and accelerates our long-term growth opportunities."

Related Contract Manufacturing:

blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors